# AbCellera Biologics (ABCL) — Analyst Forecast

ABCL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/abcl/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 1 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $9.00 | $16.50 | $30.00 | 6 |

Last price $12.68 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | UBS | Initiated Coverage | Buy | $18.00 |
| Sep 29, 2026 | JP Morgan | Initiated Coverage | Overweight | $17.00 |
| Sep 24, 2026 | Goldman Sachs | Maintained | Neutral | $13.00 |
| Aug 11, 2026 | Truist Securities | Maintained | Buy | $30.00 |
| Aug 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | $12.00 |
| Aug 6, 2026 | Stifel | Maintained | Buy | $9.00 |
| Jul 7, 2026 | Benchmark | Upgraded | Hold → Buy | $11.00 |
| May 5, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | $7.00 |
| Apr 10, 2026 | Jones Trading | Initiated Coverage | Buy | $11.00 |
| Nov 7, 2025 | Leerink Partners | Downgraded | Outperform → Market Perform | $4.00 |
| Aug 8, 2025 | Stifel | Maintained | Buy | $7.00 |
| Jul 14, 2025 | Keybanc | Maintained | Overweight | $10.00 |
| Jul 7, 2025 | Leerink Partners | Initiated Coverage | Outperform | $5.00 |
| May 16, 2025 | Truist Securities | Maintained | Buy | $10.00 |
| Apr 16, 2025 | Keybanc | Maintained | Overweight | $5.00 |
| Mar 3, 2025 | Benchmark | Maintained | Hold | — |
| Feb 28, 2025 | Stifel | Maintained | Buy | $10.00 |
| Jan 8, 2025 | Keybanc | Maintained | Overweight | $4.00 |
| Nov 5, 2024 | Stifel | Maintained | Buy | $12.00 |
| Nov 5, 2024 | Benchmark | Maintained | Hold | — |

## Frequently Asked Questions

### What is the price target for ABCL stock?

The average 12-month analyst price target for AbCellera Biologics (ABCL) is $16.50, with a high estimate of $30.00 and a low of $9.00, across 6 analysts.

### Is ABCL a buy, sell, or hold?

Analysts covering AbCellera Biologics currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ABCL?

The average price target of $16.50 implies 30.13% upside from the last price of $12.68.

### What is the latest analyst rating on ABCL?

On Oct 12, 2026, UBS initiated coverage of AbCellera Biologics at Buy with a price target of $18.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).